These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 9137453

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Tumor-specific suppressor T-cells which inhibit the in vitro generation of cytolytic T-cells from immune and early tumor-bearing host spleens.
    Bear HD.
    Cancer Res; 1986 Apr; 46(4 Pt 1):1805-12. PubMed ID: 2936451
    [Abstract] [Full Text] [Related]

  • 8. Antiestrogens sensitize human ovarian and lung carcinomas for lysis by autologous killer cells.
    Baral E, Nagy E, Krepart GV, Lotocki RJ, Unruh HW, Berczi I.
    Anticancer Res; 2000 Apr; 20(3B):2027-31. PubMed ID: 10928146
    [Abstract] [Full Text] [Related]

  • 9. The antimetastatic function of concomitant antitumor immunity. II. Evidence that the generation of Ly-1+2+ effector T cells temporarily causes the destruction of already disseminated tumor cells.
    Dye ES.
    J Immunol; 1986 Feb 15; 136(4):1510-5. PubMed ID: 3080526
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Tumor cell surface expression of granulocyte-macrophage colony-stimulating factor elicits antitumor immunity and protects from tumor challenge in the P815 mouse mastocytoma tumor model.
    Soo Hoo W, Lundeen KA, Kohrumel JR, Pham NL, Brostoff SW, Bartholomew RM, Carlo DJ.
    J Immunol; 1999 Jun 15; 162(12):7343-9. PubMed ID: 10358185
    [Abstract] [Full Text] [Related]

  • 12. Antiestrogens affect both pathways of killer cell-mediated oncolysis.
    Haeryfar SM, Nagy E, Baral E, Krepart G, Lotocki R, Berczi I.
    Anticancer Res; 2000 Jun 15; 20(3A):1849-53. PubMed ID: 10928117
    [Abstract] [Full Text] [Related]

  • 13. Progressive growth of immunogenic tumors: relationship between susceptibility of ascites P815 tumor cells to T-cell-mediated lysis and immune destruction in vivo.
    Fahey JR, Hines DL.
    Cancer Res; 1987 Sep 15; 47(18):4759-65. PubMed ID: 3113723
    [Abstract] [Full Text] [Related]

  • 14. Specific and nonspecific antitumor immunity. III. Specific T lymphocyte-mediated cytolysis of P815 mastocytoma and SL2 lymphoma by draining lymph node cells from syngeneic tumor-bearing DBA/2J mice.
    Germain RN, Williams RM, Benacerraf B.
    Am J Pathol; 1976 Dec 15; 85(3):661-74. PubMed ID: 826167
    [Abstract] [Full Text] [Related]

  • 15. Phenotype of syngeneic tumor-specific cytotoxic T-lymphocytes and requirements for their in vitro generation from tumor-bearing host and immune spleens.
    Bear HD, Susskind BM, Close KA, Barrett SK.
    Cancer Res; 1988 Mar 15; 48(6):1422-7. PubMed ID: 2964266
    [Abstract] [Full Text] [Related]

  • 16. Interleukin 2-dependent activation of tumor-specific cytotoxic T lymphocytes in vivo.
    Ley V, Langlade-Demoyen P, Kourilsky P, Larsson-Sciard EL.
    Eur J Immunol; 1991 Mar 15; 21(3):851-4. PubMed ID: 2009918
    [Abstract] [Full Text] [Related]

  • 17. Infiltration and accumulation of precursor cytotoxic T-cells increase with time in progressively growing ocular tumors.
    Ksander BR, Bando Y, Acevedo J, Streilein JW.
    Cancer Res; 1991 Jun 15; 51(12):3153-8. PubMed ID: 1904003
    [Abstract] [Full Text] [Related]

  • 18. Characterization of suppressor cells in mice bearing syngeneic mastocytoma.
    Takei F, Levy JG, Kilburn DG.
    J Immunol; 1977 Feb 15; 118(2):412-7. PubMed ID: 65423
    [Abstract] [Full Text] [Related]

  • 19. Analysis of cytotoxic T cell responses to intracameral allogeneic tumors.
    Ksander BR, Streilein JW.
    Invest Ophthalmol Vis Sci; 1989 Feb 15; 30(2):323-9. PubMed ID: 2492486
    [Abstract] [Full Text] [Related]

  • 20. Potent effector function of tumor-sensitized L-selectin(low) T cells against subcutaneous tumors requires LFA-1 co-stimulation.
    Seeley BM, Barthel SW, To WC, Kjaergaard J, Shu S, Plautz GE.
    Otolaryngol Head Neck Surg; 2001 Apr 15; 124(4):436-41. PubMed ID: 11283503
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.